<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>immunotherapy responsiveness &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/immunotherapy-responsiveness/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 04 Oct 2025 09:12:36 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>immunotherapy responsiveness &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Acylation Shapes Immunotherapy Success in Liver Cancer</title>
		<link>https://bioengineer.org/acylation-shapes-immunotherapy-success-in-liver-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 04 Oct 2025 09:12:33 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[hepatocellular carcinoma immunotherapy]]></category>
		<category><![CDATA[immunotherapy responsiveness]]></category>
		<category><![CDATA[post-translational acylation modifications]]></category>
		<category><![CDATA[prognostic gene signature]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/acylation-shapes-immunotherapy-success-in-liver-cancer/</guid>

					<description><![CDATA[Emerging research published in Genes &#038; Immunity unveils a groundbreaking prognostic signature based on post-translational acylation modifications, illuminating new frontiers in the understanding and treatment of hepatocellular carcinoma (HCC). This malignancy, known for its aggressive progression and intricate tumor microenvironment, has long posed substantial challenges to effective clinical management. The study introduces a novel methodology [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">275886</post-id>	</item>
	</channel>
</rss>
